Paul F. Lizzul - 06 Jan 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role: Chief Medical Officer
Signature: /s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol: ANAB
Transactions as of: 06 Jan 2024
Net transactions value: -$55,703
Form type: 4
Filing time: 09 Jan 2024, 19:08:05 UTC
Previous filing: 05 Jan 2024
Next filing: 19 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANAB	Common Stock	Options Exercise	$0	+6,145	+94%	$0.000000	12,672	06 Jan 2024	Direct	F1
transaction	ANAB	Common Stock	Sale	$55,703	-2,554	-20%	$21.81	10,118	08 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANAB	Restricted Stock Unit	Options Exercise	$0	-6,145	-25%	$0.000000	18,435	06 Jan 2024	Common Stock	6,145		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.